These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28962537)

  • 21. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
    J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old.
    Berges A; Laporte S; Epinat M; Zufferey P; Alamartine E; Tranchand B; Decousus H; Mismetti P;
    Br J Clin Pharmacol; 2007 Oct; 64(4):428-38. PubMed ID: 17509040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
    Malinoski D; Jafari F; Ewing T; Ardary C; Conniff H; Baje M; Kong A; Lekawa ME; Dolich MO; Cinat ME; Barrios C; Hoyt DB
    J Trauma; 2010 Apr; 68(4):874-80. PubMed ID: 20386282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.
    Rojas L; Aizman A; Ernst D; Acuña MP; Moya P; Mellado R; Cerda J
    Thromb Res; 2013; 132(6):761-4. PubMed ID: 24521789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
    Becker RC; Spencer FA; Gibson M; Rush JE; Sanderink G; Murphy SA; Ball SP; Antman EM;
    Am Heart J; 2002 May; 143(5):753-9. PubMed ID: 12040334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease.
    Brophy DF; Wazny LD; Gehr TW; Comstock TJ; Venitz J
    Pharmacotherapy; 2001 Feb; 21(2):169-74. PubMed ID: 11213853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
    Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
    Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
    Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
    Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
    JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. If some is good, more is better: An enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.
    Berndtson AE; Costantini TW; Lane J; Box K; Coimbra R
    J Trauma Acute Care Surg; 2016 Dec; 81(6):1095-1100. PubMed ID: 27244575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes.
    Green B; Greenwood M; Saltissi D; Westhuyzen J; Kluver L; Rowell J; Atherton J
    Br J Clin Pharmacol; 2005 Mar; 59(3):281-90. PubMed ID: 15752373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: a cohort study.
    Trame MN; Mitchell L; Krümpel A; Male C; Hempel G; Nowak-Göttl U
    J Thromb Haemost; 2010 Sep; 8(9):1950-8. PubMed ID: 20586920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased enoxaparin dosing is required for obese children.
    Lewis TV; Johnson PN; Nebbia AM; Dunlap M
    Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
    Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of an enoxaparin dosing calculator using burn size and weight.
    Faraklas I; Ghanem M; Brown A; Cochran A
    J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
    Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.